Data Management

Mainz Biomed announces $8M follow-on offering

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the closing of an approximately $8 million follow-on offering.

Image: Adobe Stock (generated with AI)

December 18, 2024

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the closing of an approximately $8 million follow-on offering, according to a press release.

The follow-on offering consisted of 1,367,521 units, with each unit consisting of one ordinary share (or prefunded warrant in lieu thereof), one Class A warrant to purchase one ordinary share, and one Class B warrant to purchase one ordinary share for gross proceeds of approximately $8.0 million.

Maxim Group LLC acted as the sole placing agent for the offering.